Clinical Trial Update: Human Leukocyte Antigen-A*02:01-restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of an HLA-A*02:01-restricted tumor vessel-specific peptide vaccine for advanced pancreatic cancer was terminated, with results posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• HLA-A*02:01-restricted tumor vessel-specific peptide vaccine

Snippet

Sponsor: Tokyo University | Conditions: Pancreatic Cancer, Pancreas Neoplasms | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2010-12-17